Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 19/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.37 |
| ▸ | FXR2 | P51116 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22348361 | 0.94 | NR1H4 (0.45) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348431 | 0.88 | NR1H4 (0.61) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348350 | 0.87 | NR1H4 (0.46) | NR1H4NR1I2CYP2C19CYP2C9HSD11B1 | |
| SCHEMBL22352877 | 0.83 | NR1H4 (0.35) | NR1H4 | |
| SCHEMBL22352670 | 0.83 | NR1H4 (0.44) | NR1H4NR1I2CYP2C19CYP2C9HSD11B1 | |
| SCHEMBL22347940 | 0.82 | HSD11B1 (0.44) | NR1H4NR1I2CYP2C19CYP2C9HSD11B1 | |
| SCHEMBL22348261 | 0.81 | NR1H4 (0.47) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348504 | 0.81 | NR1H4 (0.58) | NR1H4NR1I2CYP2C19CYP2C9 | |
| SCHEMBL22348553 | 0.81 | HSD11B1 (0.45) | NR1H4NR1I2CYP2C19CYP2C9HSD11B1 | |
| SCHEMBL22348556 | 0.80 | HSD11B1 (0.46) | NR1H4NR1I2CYP2C19CYP2C9HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230109670-A9 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-06 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3924337-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020168148-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168148-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | NR1H4 2/4885NR1I2 8/4885CYP2C19 1139/4885 |
| US-20230109670-A9 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | NR1H4 2/4885NR1I2 8/4885CYP2C19 1139/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | NR1H4 2/4885NR1I2 8/4885CYP2C19 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.